title: Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?
authors.affiliation: Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Hampig Raphael
authors.initials: HR
authors.lastname: Kourie
authors.affiliation: Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
authors.forename: Gil
authors.initials: G
authors.lastname: Awada
authors.affiliation: Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Ahmad Hussein
authors.initials: AH
authors.lastname: Awada
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects*; D058990:Molecular Targeted Therapy; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents
keywords: cancer; checkpoint inhibitors; clinical trial; diagnosis; future; immunotherapies; ipilimumab; nivolumab; pembrolizumab; unknown primary tumor